Title |
Improved disease markers suggest dual response in a patient with metastatic castration resistant prostate cancer and chronic lymphocytic leukemia following active cellular immunotherapy
|
---|---|
Published in |
Journal of Hematology & Oncology, May 2015
|
DOI | 10.1186/s13045-015-0149-x |
Pubmed ID | |
Authors |
Heather H. Cheng, Colleen Soleau, Evan Y. Yu |
Abstract |
Prostate cancer and chronic lymphocytic leukemia (CLL) are relatively common malignancies associated with advanced age. Although immunotherapy-based strategies are used to treat both, currently, there is no overlap in specific therapies. Sipuleucel-T is an active cellular immunotherapy that improves overall survival for patients with metastatic castration resistant prostate cancer (mCRPC) but is not typically associated with a decline in prostate-specific antigen (PSA) following administration. We report the case of a 78-year-old man with mCRPC and Rai stage 0 CLL who sustained a 12-month decline in both PSA and white blood cell (WBC) count following treatment with APC8015-2 (an investigational form of sipuleucel-T), as part of the phase II ProACT clinical trial. Two years later, the patient received commercial sipuleucel-T and again was noted to have a decline in PSA. Exploratory analysis did not clearly identify any peripheral immune markers associated with response. This case report suggests that treatment with sipuleucel-T can rarely lead to PSA decline, may have dual activity against both prostate cancer and CLL, and that these findings warrant further investigation. |
Mendeley readers
Geographical breakdown
Country | Count | As % |
---|---|---|
Unknown | 27 | 100% |
Demographic breakdown
Readers by professional status | Count | As % |
---|---|---|
Student > Doctoral Student | 4 | 15% |
Student > Bachelor | 4 | 15% |
Student > Ph. D. Student | 4 | 15% |
Lecturer | 2 | 7% |
Student > Master | 2 | 7% |
Other | 4 | 15% |
Unknown | 7 | 26% |
Readers by discipline | Count | As % |
---|---|---|
Medicine and Dentistry | 10 | 37% |
Pharmacology, Toxicology and Pharmaceutical Science | 2 | 7% |
Mathematics | 1 | 4% |
Nursing and Health Professions | 1 | 4% |
Arts and Humanities | 1 | 4% |
Other | 4 | 15% |
Unknown | 8 | 30% |